196 related articles for article (PubMed ID: 11181496)
1. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.
Ishigami M; Honda T; Takasaki W; Ikeda T; Komai T; Ito K; Sugiyama Y
Drug Metab Dispos; 2001 Mar; 29(3):282-8. PubMed ID: 11181496
[TBL] [Abstract][Full Text] [Related]
2. Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes.
Ishigami M; Takasaki W; Ikeda T; Komai T; Ito K; Sugiyama Y
Drug Metab Dispos; 2002 Aug; 30(8):904-10. PubMed ID: 12124308
[TBL] [Abstract][Full Text] [Related]
3. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
4. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Transon C; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
[TBL] [Abstract][Full Text] [Related]
5. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
[TBL] [Abstract][Full Text] [Related]
7. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
8. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
9. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
11. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors.
Fujino H; Saito T; Tsunenari Y; Kojima J; Sakaeda T
Xenobiotica; 2004; 34(11-12):961-71. PubMed ID: 15801541
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
[TBL] [Abstract][Full Text] [Related]
15. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
16. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
[TBL] [Abstract][Full Text] [Related]
17. Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins.
Filppula AM; Hirvensalo P; Parviainen H; Ivaska VE; Lönnberg KI; Deng F; Viinamäki J; Kurkela M; Neuvonen M; Niemi M
Drug Metab Dispos; 2021 Aug; 49(8):658-667. PubMed ID: 34045219
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
19. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
